143 related articles for article (PubMed ID: 32862362)
1. High-dose
Wakabayashi H; Kayano D; Inaki A; Araki R; Kuroda R; Ikawa Y; Fujiki T; Akatani N; Yamase T; Watanabe S; Hiromasa T; Kunita Y; Mori H; Saito S; Nishimura R; Wada T; Kinuya S
Ann Nucl Med; 2020 Nov; 34(11):840-846. PubMed ID: 32862362
[TBL] [Abstract][Full Text] [Related]
2. High-dose
Kayano D; Wakabayashi H; Nakajima K; Kuroda R; Watanabe S; Inaki A; Toratani A; Akatani N; Yamase T; Kunita Y; Hiromasa T; Takata A; Mori H; Saito S; Araki R; Taki J; Kinuya S
Ann Nucl Med; 2020 Jun; 34(6):397-406. PubMed ID: 32219730
[TBL] [Abstract][Full Text] [Related]
3. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
Anongpornjossakul Y; Sriwatcharin W; Thamnirat K; Chamroonrat W; Kositwattanarerk A; Utamakul C; Sritara C; Chokesuwattanasakul P; Thokanit NS; Pakakasama S; Anurathapan U; Pongphitcha P; Chotipanich C; Hongeng S
Nucl Med Commun; 2020 Apr; 41(4):336-343. PubMed ID: 31939898
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Use of Post-therapy
Wakabayashi H; Kayano D; Inaki A; Araki R; Kuroda R; Akatani N; Yamase T; Watanabe S; Hiromasa T; Kunita Y; Mori H; Saito S; Ikawa Y; Fujiki T; Kinuya S
Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32887257
[No Abstract] [Full Text] [Related]
6. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
7. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
8. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
Mazloom A; Louis CU; Nuchtern J; Kim E; Russell H; Allen-Rhoades W; Krance R; Paulino AC
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):858-62. PubMed ID: 25245583
[TBL] [Abstract][Full Text] [Related]
9. Anatomic patterns of relapse and progression following treatment with
Fishel Ben Kenan R; Polishchuk AL; Hawkins RA; Braunstein SE; Matthay KK; DuBois SG; Haas-Kogan DA
Pediatr Blood Cancer; 2022 Feb; 69(2):e29396. PubMed ID: 34662499
[TBL] [Abstract][Full Text] [Related]
10. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
11. [131-I-meta-iodo-benzyl-guanidine therapy in childhood neuroblastoma.].
Gilitsch A; Vojcek Á; Mezősi E; Bán Z; Csernus K; Ottóffy G
Orv Hetil; 2023 Oct; 164(39):1550-1555. PubMed ID: 37778009
[TBL] [Abstract][Full Text] [Related]
12. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
13. Radiation exposure in nurses during care of
Taniguchi Y; Wakabayashi H; Inaki A; Kayano D; Yamada M; Kinuya S
Ann Nucl Med; 2020 Jun; 34(6):441-447. PubMed ID: 32297135
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
15. Combined use of chemotherapy and 131I-metaiodobenzylguanidine in the treatment of advanced-stage neuroblastoma.
Sari O; Uğur O; Emir S; Akyüz C
Turk J Pediatr; 2001; 43(1):29-33. PubMed ID: 11297155
[TBL] [Abstract][Full Text] [Related]
16. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II clinical trial of high-dose [
Kuroda R; Wakabayashi H; Araki R; Inaki A; Nishimura R; Ikawa Y; Yoshimura K; Murayama T; Imai Y; Funasaka T; Wada T; Kinuya S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1574-1583. PubMed ID: 34837510
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry-based high-activity therapy with
Genolla J; Rodriguez T; Minguez P; Lopez-Almaraz R; Llorens V; Echebarria A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1567-1575. PubMed ID: 30838430
[TBL] [Abstract][Full Text] [Related]
19. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
20. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]